Topics

Multi-Pathway Targeting Strategies For Osteoarthritis

Chronic Inflammation Cellular Degeneration Cellular Stress Proteostasis

Osteoarthritis is a heterogeneous whole-joint disease involving cartilage, synovium, subchondral bone, meniscus, ligaments, periarticular muscle, and pain pathways. Multi-pathway targeting strategies emerged because osteoarthritis is not only cartilage "wear and tear," but a disease process shaped by mechanical stress, inflammation, extracellular matrix degradation, bone remodeling, metabolic dysfunction, cellular senescence, and pain sensitization[1][2][3][4].

The core mechanisms support parallel intervention points. IL-1β, TNF, IL-6, NF-κB, and prostaglandin pathways amplify synovitis and inflammatory catabolism; MMPs and ADAMTS enzymes degrade collagen and aggrecan; Wnt, TGFβ, BMP, FGF18, and subchondral bone signals regulate cartilage anabolism, chondrocyte hypertrophy, osteophytes, and bone remodeling; NGF signaling drives osteoarthritis pain; senescent chondrocytes and synovial cells produce a secretory inflammatory phenotype that worsens joint degeneration[3][4][5][6][7][8][9][10].

Current applications divide osteoarthritis drug discovery into cartilage-driven, synovitis-driven, bone-driven, pain-driven, and senescence-driven strategies. Sprifermin, an FGF18 agent, increased femorotibial cartilage thickness in knee osteoarthritis, while clinical symptom benefit remained uncertain. Lorecivivint modulates Wnt signaling and was tested for pain and structural progression in symptomatic knee osteoarthritis. Tanezumab, an anti-NGF antibody, improved pain and function but raised concern about rapidly progressive osteoarthritis. Senolytic clearance of senescent cells reduced post-traumatic osteoarthritis features and promoted a pro-regenerative environment in experimental models[7][8][9][10].

The main gap is that no broadly approved disease-modifying osteoarthritis drug has yet aligned structural modification, durable symptom relief, safety, and patient selection. Future strategies should combine pathway-specific drugs with phenotype-guided trial design, imaging biomarkers, synovial and cartilage molecular markers, local delivery, and rational combinations that target inflammation, matrix breakdown, pain, senescence, and bone remodeling without disrupting joint homeostasis[3][4][7][8][9][10].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-13418 Dorsomorphin dihydrochloride
Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
Organoid   AMPK   TGF-β Receptor   Autophagy  
Colorectal Cancer   Prostate Cancer   Ovarian Cancer   Pain   Digestive System Inflammation   Obesity  
819
HY-13418A Dorsomorphin
Dorsomorphin (BML-275) is a selective and ATP-competitive AMPK inhibitor (Ki=109 nM in the absence of AMP). Dorsomorphin (BML-275) selectively inhibits BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
Organoid   AMPK   TGF-β Receptor   Autophagy  
819
HY-10431 SB-431542
SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways.
Organoid   TGF-β Receptor   Apoptosis  
Colorectal Cancer   Prostate Cancer   Pancreatic Cancer   Digestive System Inflammation   Obesity   Lung Fibrosis  
323
HY-10432 A 83-01
A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
Organoid   TGF-β Receptor  
Cancer  
144
HY-13013 SIS3
SIS3 is a potent and selective inhibitor of Smad3 with an IC50 of 3 μM for Smad3 phosphorylation. SIS3 inhibits the myofibroblast differentiation of fibroblasts by TGF-β1.
TGF-beta/Smad  
Inflammation or Immune System Disease   Colorectal Cancer   Prostate Cancer   Lung Fibrosis  
113
HY-B0673 Pirfenidone
Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities.
TGF-beta/Smad   CCR  
Colorectal Cancer   Prostate Cancer   Viral Infection   Digestive System Inflammation   SARS-CoV-2 Infection   Lung Fibrosis   Rheumatoid Arthritis  
96
HY-12071 LDN193189
LDN193189 (DM-3189) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva.
Organoid   TGF-β Receptor  
Breast Cancer  
95
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-13226 Galunisertib
Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.
TGF-β Receptor  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Pancreatic Cancer   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
74
HY-100347A SRI-011381 hydrochloride
SRI-011381 hydrochloride is an orally active TGF-β signaling agonist, exhibits neuroprotective effects, with blood-brain barrier permeability.
TGF-beta/Smad  
Neurological, Eye or Ear Disease   Liver Cancer  
61
HY-100347 SRI-011381
SRI-011381 is an orally active TGF-β signaling agonist, exhibits neuroprotective effects.
TGF-beta/Smad  
Neurological, Eye or Ear Disease   Liver Cancer  
61
HY-16268 Kartogenin
Kartogenin (KGN) is an inducer of chondrogenic tissue formation (EC50: 100 nM). Kartogenin induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research.
TGF-beta/Smad  
Inflammation or Immune System Disease   Liver Cancer  
33
HY-13012 RepSox
RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes.
Organoid   TGF-β Receptor  
Colorectal Cancer   Prostate Cancer   Pancreatic Cancer   Glucose Metabolism   Obesity   Lung Fibrosis  
23
HY-N1584 Halofuginone
Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects.
DNA/RNA Synthesis   TGF-beta/Smad   Parasite   Sodium Channel   Calcium Channel  
Inflammation or Immune System Disease   Ovarian Cancer   Parasitic Infection   Pulmonary Hypertension  
22
HY-N0439 Asiaticoside
Asiaticoside, a trisaccaride triterpene from Centella asiatica, suppresses TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts; Asiaticoside shows antioxidant, anti-inflammatory, and anti-ulcer properties.
p38 MAPK   TGF-beta/Smad   Reactive Oxygen Species (ROS)   Apoptosis   Endogenous Metabolite  
Digestive System Disease   Lung Cancer   Neurodegenerative Disease   Pain   Digestive System Inflammation   Cardiovascular Disease  
19
HY-12273 DMH-1
DMH-1 is a selective BMP inhibitor. DMH-1 upregulates the expression of SOX1. DMH-1 increases cardiomyocyte progenitor cells and promotes the differentiation of mouse embryonic stem cells into cardiomyocytes. DMH-1 induces the differentiation of hiPSC-derived neural progenitor cells into β3-tubulin-positive neurons.
TGF-β Receptor   Organoid   Microtubule/Tubulin  
Neurological, Eye or Ear Disease   Heart Disease  
15
HY-116084 Trimethylamine N-oxide
Trimethylamine N-oxide is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway.

Source: Host intestinal bacteria

Drug Metabolite   NOD-like Receptor (NLR)   Reactive Oxygen Species (ROS)   TGF-beta/Smad   Endogenous Metabolite  
Liver Cancer   Depression   Autoimmune Disease   Cardiovascular Disease  
12
HY-P99241 Ponsegromab
Ponsegromab is a Growth differentiation factor 15 (GDF15) inhibitor with human, cynomolgus monkey, and mouse target IC50 values of 0.123 nM, 0.053 nM, and 0.102 nM, respectively. Ponsegromab acts as a chemosensitizer, increases intracellular reactive oxygen species, reduces glutathione levels. Ponsegromab can be used for the research of oxaliplatin-resistant colorectal cancer.

Species: Human

TGF-beta/Smad   TGF-β Receptor  
Breast Cancer   Non-Small Cell Lung Cancer  
3
HY-P99355 Bimagrumab
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness.

Species: Human

TGF-β Receptor  
Metabolic or Endocrine Disease  
3
HY-W016562 Hippuric acid
Hippuric Acid is an orally active metabolite. Hippuric Acid can be produced by intestinal microorganisms from the metabolism of polyphenols, benzoic acid. Hippuric Acid decreases NRF2, MMP9 and leads to ROS accumulation. Hippuric Acid activates TGFβ/SMAD signaling. Hippuric Acid improves hyperuricemia and colitis. Hippuric Acid can also be used in cardiovascular disease research. .
Endogenous Metabolite   Keap1-Nrf2   MMP   Reactive Oxygen Species (ROS)   TGF-beta/Smad  
Colorectal Cancer   Cardiovascular Disease   Colitis   Hyperuricemia   Rheumatoid Arthritis  
2

References

[1]. Hunter DJ, et al. Osteoarthritis. Lancet. 2019;393(10182):1745-1759.  [Content Brief]

[2]. Loeser RF, et al. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697-1707.  [Content Brief]

[3]. Latourte A, et al. Emerging pharmaceutical therapies for osteoarthritis. Nat Rev Rheumatol. 2020;16(12):673-688.  [Content Brief]

[4]. Cho Y, et al. Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions. Exp Mol Med. 2021;53(11):1689-1696.  [Content Brief]

[5]. Goldring MB, et al. Inflammation in osteoarthritis. Curr Opin Rheumatol. 2011;23(5):471-478.  [Content Brief]

[6]. Glasson SS, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature. 2005;434(7033):644-648.  [Content Brief]

[7]. Hochberg MC, et al. Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis. JAMA. 2019;322(14):1360-1370.  [Content Brief]

[8]. Yazici Y, et al. Lorecivivint, a novel intraarticular CDC-like kinase 2 and dual-specificity tyrosine phosphorylation-regulated kinase 1A inhibitor and Wnt pathway modulator, for knee osteoarthritis. Arthritis Rheumatol. 2020;72(10):1694-1706.  [Content Brief]

[9]. Schnitzer TJ, et al. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee. JAMA. 2019;322(1):37-48.  [Content Brief]

[10]. Jeon OH, et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat Med. 2017;23(6):775-781.  [Content Brief]

Keywords

osteoarthritis, multi-pathway targeting, DMOADs, cartilage degradation, synovitis, subchondral bone remodeling, Wnt signaling, FGF18, NGF, senolytics